Sensei Biotherapeutics: Piper Sandler starts with "overweight" on immunotherapy platform potential

Faeth Therapeutics,

01/03/2021 11:00

** Piper Sandler initiates coverage of drug developer Sensei
Biotherapeutics  SNSE.O  with an "overweight" rating and a $25
PT
    ** Brokerage's PT on stock represents an upside of about 52%
to SNSE's closing price on Friday
    ** Brokerage views co's ImmunoPhage as highly differentiated
and says its ability to generate tumor-specific T cells can
potentially broaden therapeutic benefit of PD-L1 inhibitors
platform 
    ** Additional data from co's early-to-mid stage trial of its
lead candidate SNS-301 in combination with cancer drug Keytruda
in head and neck cancer patients could be an opportunity for 
significant share appreciation - Piper Sandler
    ** Says the data could "validate ImmunoPhage's ability to
expand the depth and breadth of PD-1 utility"
    ** Co last year reported positive early data from a trial
testing the safety, efficacy and immunogenicity of SNS-301 head
and neck cancer patients (https://bit.ly/2MyDGzN)
    ** SNSE had fallen 12.7% since its market debut last month

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))